Omnicell (NASDAQ:OMCL) Given New $64.00 Price Target at Craig Hallum

Omnicell (NASDAQ:OMCL) had its target price boosted by Craig Hallum from $45.00 to $64.00 in a report issued on Thursday, Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts also recently issued reports about the company. StockNews.com raised Omnicell from a “hold” rating to a “buy” rating in a research note on Saturday, October 19th. Bank of America reaffirmed a “neutral” rating and issued a $57.00 price target (up from $44.00) on shares of Omnicell in a research report on Thursday. Barclays upgraded shares of Omnicell from an “underweight” rating to an “equal weight” rating and increased their target price for the company from $26.00 to $39.00 in a research note on Friday, August 2nd. Wells Fargo & Company boosted their price target on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. Finally, Benchmark reissued a “buy” rating and issued a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $50.83.

Omnicell Price Performance

NASDAQ OMCL opened at $48.67 on Thursday. The company has a current ratio of 1.05, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47. The company has a market cap of $2.24 billion, a PE ratio of -124.79, a PEG ratio of 53.62 and a beta of 0.81. Omnicell has a 1 year low of $25.12 and a 1 year high of $55.74. The stock’s 50-day moving average price is $43.34 and its two-hundred day moving average price is $35.44.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a positive return on equity of 2.55% and a negative net margin of 1.66%. The firm had revenue of $276.80 million during the quarter, compared to analyst estimates of $254.41 million. During the same period last year, the company posted $0.29 EPS. The business’s quarterly revenue was down 7.4% compared to the same quarter last year. On average, analysts predict that Omnicell will post 0.64 EPS for the current year.

Institutional Investors Weigh In On Omnicell

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Omnicell by 1.4% in the first quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock valued at $165,200,000 after acquiring an additional 80,312 shares during the last quarter. Pacer Advisors Inc. boosted its position in shares of Omnicell by 32.6% during the second quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock worth $56,047,000 after buying an additional 508,789 shares during the period. Champlain Investment Partners LLC grew its stake in shares of Omnicell by 16.0% during the 1st quarter. Champlain Investment Partners LLC now owns 1,753,205 shares of the company’s stock worth $51,246,000 after acquiring an additional 241,235 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Omnicell by 0.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock worth $31,955,000 after buying an additional 3,570 shares in the last quarter. Finally, Federated Hermes Inc. raised its holdings in Omnicell by 1,113.6% during the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock worth $26,830,000 after acquiring an additional 909,480 shares in the last quarter. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.